Last reviewed · How we verify

Enbrel biosimilars

Complete Enbrel (etanercept) biosimilar landscape: 11 approved biosimilars, 0 filed, 4 in Phase 3. Sponsor, approval status, first approval date, and patent timeline for the originator.

11 approved 0 filed 4 Phase 3 All key patents expired

About Enbrel

Enbrel (etanercept) — originally marketed by Immunex. Class: Tumor Necrosis Factor Blocker [EPC]. Target: Tumor necrosis factor. Area: Oncology. First approved 1998-01-01.

Approved biosimilars (11)

BiosimilarSponsorPhaseFirst approvalCountry
etanercept or adalimumab University of Glasgow marketed
Etanercept (ENBREL®) Amgen marketed
Etanercept via Autoinjector A Amgen marketed
Etanercept (ETN) University of Leeds marketed
etanercept (EnbrelTM) Wyeth is now a wholly owned subsidiary of Pfizer marketed
Etanercept + Acitretin Pfizer marketed
ETICOVO SAMSUNG BIOEPIS CO LTD marketed
Etanercept via Autoinjector B Amgen marketed
Etanercept, methotrexate and depomedrone University Hospital Birmingham marketed
Etanercept 50 mg Centocor, Inc. marketed
Etanercept + Methotrexate Wyeth is now a wholly owned subsidiary of Pfizer marketed

Filed biosimilars under regulatory review (0)

No biosimilars currently under regulatory review.

Phase 3 biosimilars (4)

BiosimilarSponsorPhaseFirst approvalCountry
Etanercept / Autoinjector A Amgen phase 3
GP2015 Etanercept Sandoz phase 3
etanercept Treatment Assistance Publique Hopitaux De Marseille phase 3
Etanercept Liquid Amgen phase 3

Originator patent timeline

Active patents (0)

No active patents tracked.

Expired patents (0)

No expired patents tracked.

Subscribe to biosimilar updates

Every regulatory action on Enbrel or any of its biosimilars:

Related